|
Fred Driscoll joined Genelabs in October 2007 as Chief Financial Officer bringing more than 30 years of financial management and operational experience in the biotechnology and medical device industries to Genelabs. He was previously with Astraris Inc. a start up biotechnology company developing vascular disrupting technology to treat solid tumors where he served as Chief Financial Officer. From 2000 to 2006 he was employed by OXiGENE Inc. initially as Vice President Finance and Operations and subsequently as President and Chief Executive Officer. From 1996-2000 he served as Senior Vice President of Finance and Operations for Collagenesis Corporation and from 1974-2006 he served in numerous key financial positions including Corporate Controller and Vice President Finance Americas for Instrumentation Laboratory. | 